Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms

Eleftherios Chatzellis,Anna Angelousi,Kosmas Daskalakis,Marina Tsoli,Krystallenia I. Alexandraki,Ewa Wachuła,Amichay Meirovitz,Ofra Maimon,Simona Grozinsky-Glasberg,David J. Gross,Beata Kos Kudła,Anna Koumarianou,Gregory Kaltsas

Activity and Safety of Standard and Prolonged Capecitabine/Temozolomide Administration in Patients with Advanced Neuroendocrine Neoplasms

2019

Eleftherios Chatzellis
Anna Angelousi
Kosmas Daskalakis
Marina Tsoli
Krystallenia I. Alexandraki
Ewa Wachuła
Amichay Meirovitz
Ofra Maimon
Simona Grozinsky-Glasberg
David J. Gross
Beata Kos Kudła
Anna Koumarianou
Gregory Kaltsas

Background: Capecitabine and temozolomide combination (CAPTEM) is associated with high response rates in patients with advanced neuroendocrine neoplasms (NENs). We evaluated the real-world activity ...

Keywords:

Capecitabine
Endocrinology
Diabetes mellitus
Oncology
Temozolomide
Internal medicine
Biology
in patient
Gastroenterology
Neuroendocrine tumors
Univariate analysis
Progressive disease
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations